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Abstract
Soluble cytokine receptors are normal constituents of body fluids that regulate peripheral cytokine and lymphoid activity.
Levels of soluble IL-2 receptors (sIL-2R) are elevated in psychiatric disorders linked with autoimmune processes, including
ones in which repetitive stereotypic behaviors and motor disturbances are present. However, there is no evidence that sIL-
2Rs (or any peripheral soluble receptor) induce such behavioral changes, or that they localize in relevant brain regions. Here,
we determined in male Balb/c mice the effects of single peripheral injections of sIL-2Ra or sIL-2Rb (0–2 mg/male Balb/c
mouse; s.c.) on novelty-induced ambulatory activity and stereotypic motor behaviors. We discovered that sIL-2Ra increased
the incidence of in-place stereotypic motor behaviors, including head up head bobbing, rearing/sniffing, turning, and
grooming behavior. A wider spectrum of behavioral changes was evident in sIL-2Rb-treated mice, including increases in
vertical and horizontal ambulatory activity and stereotypic motor movements. To our knowledge, this is the first
demonstration that soluble receptors induce such behavioral disturbances. In contrast, soluble IL-1 Type-1 receptors (0–
4 mg, s.c.) didn’t appreciably affect these behaviors. We further demonstrated that sIL-2Ra and sIL-2Rb induced marked
increases in c-Fos in caudate-putamen, nucleus accumbens and prefrontal cortex. Anatomical specificity was supported by
the presence of increased activity in lateral caudate in sIL-2Ra treated mice, while sIL-2Rb treated mice induced greater c-
Fos activity in prepyriform cortex. Moreover, injected sIL-2Rs were widely distributed in regions that showed increased c-Fos
expression. Thus, sIL-2Ra and sIL-2Rb induce marked subunit- and soluble cytokine receptor-specific behavioral
disturbances, which included increases in the expression of ambulatory activity and stereotypic motor behaviors, while
inducing increased neuronal activity localized to cortex and striatum. These findings suggest that sIL-2Rs act as novel
immune-to- brain messengers and raise the possibility that they contribute to the disease process in psychiatric disorders in
which marked increases in these receptors have been reported.
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Introduction
Soluble cytokine receptors (SCR) are circulating proteins that
lack the extracellular portion of their membrane counterparts.
SCRs are normal constituents of body fluids that regulate cytokine
and lymphoid activity [1–3]. The first SCR to be characterized -
the soluble interleukin-2 receptor (sIL-2R), regulates IL-2 family
cytokine activity [1]. The membrane bound IL-2 receptor is
composed of a, b, and c subunits, and is normally expressed on T
and B lymphocytes, among other cells in the immune and central
nervous systems [4,5]. While the bulk of data concerning soluble
forms of the IL-2R has focused on the alpha subunit (sIL-2Ra), a
soluble form of the beta subunit (sIL-2Rb) has also been
characterized [6].
Serum levels of sIL-2Rs are markedly increased in disease states
associated with immune activation, such as autoimmune, infec-
tious, and neoplastic disorders [7,8]. A positive correlation
between sIL-2R’s levels and disease progression has been observed
in certain immunologically based disorders [9]. As such, they may
serve as important biomarkers of disease activity in conditions
linked to immune activation. An intriguing aspect to the sIL-2R-
immune activation relationship is that increased levels of sIL-2Rs
are evident in psychiatric disorders linked to autoimmune
conditions and associated with a psychomotor activation, repet-
itive stereotyped movements, and other motor disturbances. For
example, numerous investigators have shown that serum and/or
cerebrospinal levels of sIL-2Rs are increased in schizophrenic
patients [10–15]. It was further shown that increased levels of sIL-
2Ra occur coincident with an increased expression of motor
disturbances in subsets of schizophrenic patients, including
neuroleptic-naı ¨ve patients [16] and medicated patients with
tardive dyskinesia [17]. sIL-2Ra are also increased in acute mania
but not during remission [18,19], suggesting a link between sIL-2R
and psychomotor activation.
In view of the link between sIL-2Rs and psychiatric disorders
involving motor disturbances, an intriguing possibility is that sIL-
2Rs may precipitate such disturbances. The fact that sIL-2Rs
regulate cytokine and lymphoid activity supports this view.
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receptor) provoke such behavioral changes. As well, there is no
evidence that peripheral sIL-2Rs accumulate in the brain. Such a
finding would have wide ranging implications. Accordingly, in the
present investigation we sought to determine in male Balb/c mice
whether single peripheral injections of sIL-2Ra or sIL-2Rb induce
variations in motor activity and repetitive stereotyped movements,
and whether they stimulate activity and accumulate in brain
regions that act as important neural substrates of such behaviors,
including the caudate-putamen, nucleus accumbens, and motor
and prefrontal cortices.
Materials and Methods
Subjects
All methods and procedures were approved by Institutional
Animal Care and Use Committee (IACUC) of UMDNJ, Newark,
NJ. A total of 92 adult male Balb/c mice (Charles River
Laboratories, Wilmington, MA) were used in the present study.
We used male Balb/c mice to maintain consistency with previous
studies from our laboratory examining behavioral and neural
consequences of IL-2 treatment [20,21]. The mice were housed in
standard polypropylene ‘shoebox’ cages in groups of four until
testing whereupon they were individually housed. The animals
were maintained on a 12 hour light/12 hour dark light cycle (7
am–7 pm), and permitted free access to standard laboratory chow
and water. For behavioral testing, 4–7 mice/group were used for
the tests and received single subcutaneous injection of either
Saline, sIL-2Ra (0.5 mg–2 mg/mouse), sIL-2Rb (1 mg–2 mg/
mouse) or sIL-1R1 (1 mg–8 mg/mouse). For fluorescent labeling
we used 4 mice in each group, whereas 8–12 mice/group were
used for c-fos immunohistochemistry experiment. Behavioral
experiments were conducted multiple time using different mice
in order to determine stable and reproducible effects of drug
administration.
Drugs
Recombinant human sIL-2Ra was obtained from Peprotech
(Rockhilll, NJ), where as recombinant human carrier free sIL-2Rb
and sIL-1R1 were obtained from R&D Systems (Minneapolis,
MN).
Behavioral Testing
Immediately following injections, the mice were individually
placed into a test arena (TruScan Behavioral Monitoring System;
Coulbourn Instruments, PA) in normal illumination for 2-hr. A
series of behavioral measurements were recorded including
locomotion, vertical activity, horizontal and vertical stereotypic
movements, jumps, and turns. Locomotion was defined as the sum of
all vectored coordinate changes in the floor plane, and included
floor plane total movement distance less the stereotypic movement
distance. Vertical activity was defined as total movements in the
vertical plane. Each movement is a series of successive coordinate
changes with no rest (same coordinates) for at least 1 sample
interval. Horizontal stereotypic movements were defined as the total
number of coordinate changes 61.499 beam spaces in the floor
plane (X and Y) dimension and back to the original point that do
not exceed 2 seconds apart. Three such movements must be made
before a stereotypy episode starts. When it does, the qualifying 3
movements are included in the total number of moves. Vertical
stereotypic movements’ measures are analogous to those in the floor
plan except that only vertical movements are measured. Jumps
were defined as the total number of time-contiguous 0-0
coordinate sets that do not exceed 2 seconds. Turns were defined
as movements where the animal enters 4 radially-contiguous
quadrants in ascending or descending order, without interruption.
The test sessions were also filmed with a VHS camera, and at a
later date, an experienced rater blinded to the treatment groups
scored the incidence and duration of stereotypic behaviors, which
included sniffing, head bobbing, and intense grooming. We
selected these stereotypies based on our findings that IL-2
treatment induces an increase in stereotypic motor behavior
[21], unpublished data showing that such behaviors may be
induced by elements of an activated immune system, and their
utility as animal analogous of repetitive stereotyped movements.
The time engaged in head bobbing was defined as the time (sec)
engaged in repeated vertical head bobbing. A minimum of 3-sec of
uninterrupted head bobbing was defined as one episode. The
duration of such episodes was recorded with a stopwatch. Sniffing
was defined as the time (sec) engaged in head-up and head-down
sniffing with the head/snout directed towards the top of the cage
or down toward the floor of the cage, respectively. We also
measured the duration of such episodes as well as continuous
sniffing for at least 5-sec. Measurements were taken 20-, 40-, 60-,
80-, 100- and 120- min after injection in 2-min epochs. Results are
presented as totals (6 SEM) for the entire session.
c-Fos immunohistochemistry
The mice received a single injection of saline, sIL-2Ra (1 mg/
mouse, s.c.) and sIL-2Rb (2 mg/mouse, s.c.) and immediately
thereafter were placed into an open field for 2-hr. Immediately
following the test session, the mice were deeply anesthetized with
Sodium pentobarbital (60–80 mg/kg, i.p.) and transcardially
perfused with 0.9% saline (pH 7.2) followed by 4% paraformal-
dehyde (pH 7.4). After perfusion, brains were removed from the
skull and then placed in 4% paraformaldehyde solution at 4uC for
overnight. The brains then were transferred to 30% sucrose
solution at 4uC until they sank to the bottom whereupon they were
frozen in a cryostat (Leica CM1900) at 220uC for slow freezing.
Sections were cut at 30 mm thickness and alternate sections were
transferred to 24 well plates containing PBS, and washed for 30-
min. Sections were then incubated on a rocker table with rabbit
antibody to c-fos protein (Santa Cruz, CA) diluted in 1:500 in a
PBS solution containing 1% normal goat serum and 0.3% Triton
X-100 overnight at 4uC. The next day, sections were washed with
PBS and incubated in biotinylated goat anti-rabbit antibody
(1:333, Vector Labs, Burlingame, CA) in PBS for 1 h. Sections
were then rinsed in PBS, incubated for 90- min in Avidin–Biotin/
Peroxidase (ABC Elite, Vector Labs), and washed 3 times in PBS.
The sections were then treated with a ready-made stabilized
solution of active Diaminobenzidine (‘Stable DAB’, Invitrogen)
until completion of the reaction (10 min), and again washed, then
dehydrated with alcohol, treated with Xylene, and cover slipped
with Permount (Sigma-Aldrich). Slides were viewed with an
Olympus AX-70 microscope and photographed with a Magnafire
digital camera. Composite images were taken at 46magnification
using Neurolucida software (Microbrightfield Inc., Williston, VT).
Fluorescent labeling for sIL-2Ra and sIL-2Rb
Brain sections were first blocked with 5% normal goat serum
containing 0.3% Triton X-100 in PBS for 1 hr and then incubated
with anti-human sIL-2Ra monoclonal antibody (1:100 dilution) or
anti-human IL-2Rb affinity purified polyclonal antibody (1:100
dilution) overnight at 4uC followed by incubation with goat anti-
human IgG-FITC (green, 1:200; Santa Cruz, CA) secondary
antibody for 1 h at room temperature. Then the slices were
mounted on a slide, and viewed under an Olympus fluorescence
microscope.
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We defined the areas to be counted bilaterally as: (1) (a)
Caudate-Putamen, and (b) sub-territories within the caudate-
putamen, including the dorsomedial (DM), dorsolateral (DL),
central (CT), ventromedial (VM), and ventrolateral (VL) aspects;
(2) (a) Nucleus Accumbens, and (b) compartments within the
nucleus accumbens, including the shell (SH) and core (CO); (3)
Motor Cortex, including M1 and M2 divisions; (4) Cingulate
Cortex; (5) Infralimbic Cortex; (6) Sensorimotor cortex; and (7)
Prepyriform cortex. Black and white Kodalith image masks were
subsequently created, permitting Fos-immunoreactive cells to be
converted into individual black dots, while everything else was
eliminated as a white background. These image masks were then
processed and particles no smaller than 10 pixels (to exclude
background staining artifacts), and no larger than 50 pixels (to
eliminate large areas of immunoreactivity such as non-specific
staining at the edge or at folds in the tissue were counted. Each
Fos-positive nucleus was marked with an asterisk. Using
Neuroexplorer (Microbrightfield Inc., Williston, VT) software,
we then counted the number of immunoreactive nuclei present
Figure 1. Behavioral effects induced by single injection of sIL-2Ra. sIL-2Ra –induced locomotor changes and repetitive stereotyped
movements. Mean (6 S.E.M.) activity scores for; (A) Head bobbing (B) Jumping (C) Turning (D) Rearing/Sniffing duration (E) Locomotion and (F)
Horizontal Stereotypic Movements following single injections of sIL-2Ra (0, 0.5,1 and 2 mg/mouse, s.c.).
doi:10.1371/journal.pone.0036316.g001
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Data from c-Fos immunohistochemistry (number of Fos-immuno-
reactive cells) were counted from 3 sections per animal and 4
animals for each treatment were then submitted to one-way
ANOVA, with an accepted level of significance of p,0.05.
We used Adobe Photoshop to generate an overlay image for c-
Fos and Immunofluorescent combined image. Individual images
of c-Fos and Fluorescent staining of each region from various
treatment groups were selected and overlayed to visualize both
staining at optimal level.
Results
Behavior of sIL-2Ra treated mice
sIL-2Ra treated mice displayed increased novelty-induced
stereotypic behaviors. In particular, sIL-2Ra treated mice showed
dose-dependent increased head-bobbing [F (3, 19)=7.62,
Figure 2. Behavioral effects induced by single injection of sIL-2Rb. sIL-2Rb–induced locomotor changes and repetitive stereotyped
movements. Mean (6 S.E.M.) activity scores for; (A) Locomotion (B) Horizontal Stereotypic Movements (C) Turning (D) Head bobbing (E) Rearing/
Sniffing duration and (F) Jumping following single injections of sIL-2Rb (0, 1 and 2 mg/mouse, s.c.).
doi:10.1371/journal.pone.0036316.g002
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figure 1b], and turning (F (3, 20)=1.87, p=0.04) (figure 1c).
The sIL-2Ra treated mice also spent more time exhibiting in-place
stereotypic activity as evident by increased rearing (F (3,
19)=3.79, p=0.01) (figure 1d). Additionally, these mice showed
a tendency for higher locomotion (F (3, 20)=3.18, p=0.06)
(Figure 1e), with more horizontal stereotypic movement as
compared to control mice; however, these findings were not
statistically significant (F (3, 20)=4.23, p=0.07) (figure 1f).
Behavior of sIL-2Rb treated mice
sIL-2Rb treated mice displayed increased novelty-induced
locomotion and stereotypic behaviors as compared to control
mice. sIL-2Rb treated mice showed dose-dependent increased
locomotion (F (2, 17)=3.85, p=0.04) (Figure 2a), increased
horizontal stereotypic movement (F (2, 17)=3.95, p=0.04)
(figure 2b) and turning (F (2, 17)=3.20, p=0.05) (figure 2c).
The sIL-2Rb treated mice spent more time exhibiting in-place
stereotypic activity as evident by increased head-bobbing [F (2,
17)=6.02, p=0.02; figure 2d] and also increased rearing (F (2,
17)=3.72, p=0.01) (figure 2e). These mice also showed a
tendency for more Jumping compared to controls, but this finding
was not statistically significant [F (2, 17)=1.56, p=0.24; figure 2f].
Behavior of IL-1R1 treated mice
As shown in Table 1, when treated with sIL-1R1 mice were not
significantly different from controls (saline treated mice) for
locomotor activity (p=0.15), stereotypic movements (p=0.5),
turning (p=0.47), rearing (p=0.94) and head bobbing (p=0.37).
These findings demonstrate that the specificity of stereotypic
effects described above for sIL-2Rs do not extend to animals
treated with sIL-1R1.
Effects of single injections of recombinant sIL-2a and sIL-
2Rb on c-Fos immunoreactivity in cortico-striatal regions
We showed that single injections of sIL-2Ra and sIL-2Rb
induce subunit-specific alterations in novelty stress-induced motor
activity, which includes increased locomotion, vertical activity, and
stereotypic behaviors. These findings imply that these soluble
receptors modulate cell activity in cortico-striatal regions.
However, to our knowledge, there is no evidence that a soluble
receptor of any kind modulates activity in these (or other) brain
regions. Thus, we sought to determine whether sIL-2Ra and sIL-
2Rb increase c-Fos expression in subregions of the caudate-
putamen, nucleus accumbens, and motor cortex. In order to
further examine stereotypic responses, we extended our analysis to
sniffing behavior as it may relate to activation of the prepyriform
cortex in response to the presence of odors.
A marked increase in c-Fos expression was induced by sIL-2Rs
administration in the caudate-putamen, F (2, 27)=7.530,
p=0.00007 (figures 3A–3E). Student-Newman-Keuls multiple
comparisons (a=0.05) confirmed that compared to controls,
Fos-like immunoreactivity was significantly elevated in sIL-2Ra-
treated mice (by 1.85 fold) and sIL-2Rb-treated mice (by 7 fold).
Post-hoc analyses further revealed that c-Fos expression of sIL-
2Rb-treated mice significantly exceeded those of mice receiving
sIL-2Ra. It is also important to note that a heterogeneous pattern
of c-Fos immunoreactivity was induced by both sIL-2R subunits.
Indeed, regional analyses indicated that compared with controls,
Fos expression was significantly elevated within the dorsomedial,
ventromedial, dorsolateral, ventrolateral, and central caudate in
sIL-2Ra- and sIL-2Rb-treated mice, and that the magnitude of
these increases were significantly greater in mice receiving sIL-
2Rb.
sIL-2Rs treatment induced profound increases in Fos expression
in the nucleus accumbens, F(2,25)=4.346, p=0.0250 (figures 4A–
D). Student Newman-Keuls multiple comparisons confirmed that
the total number of Fos-like immunoreactive cells in the
accumbens was significantly elevated in sIL-2Ra treated (by 28
fold) mice and in sIL-2Rb treated mice (by 24 fold) compared to
saline-treated mice (figure 4D). Although both soluble receptor
subunits induced increases in Fos expression that were similar in
magnitude, there were striking differences in the regional
distribution of these effects. Irrespective of sIL-2R subtype, sIL-
2R induced Fos expression was significantly greater in the shell of
the accumbens than in the core [F (5, 31)=3.912, p=0.0288;
figure 4D]. Moreover, throughout the accumbens, Fos expression
in sIL-2Rb treated animals was found more profound than sIL-
2Ra [F (5, 31)=3.671, p=0.0315; figure 4D].
Administration of both sIL-2Rs increased Fos-like immunore-
activity within motor cortex [F (5, 35)=27.22, p=0.0036;
figure 5A]. In sIL-2Ra-treated mice, Fos expression was increased
predominantly in the M2 part of motor cortex, which is
responsible for planning and coordination of complex movements
(figures 5B and 5E). Likewise, both sIL-2Rs increased Fos
expression in infralimbic and cingulate cortices (figures 5C, 5F
and 5G), which are believed to be linked more closely with
emotional behaviors. However, greater quantities of labeling were
manifest in these regions following sIL-2Rb administration.
In prepyriform cortex, which is believed to be an extension of
primary olfactory cortex, significant 5 fold increases in induction of
Fos-like immunoreactivity were only shown in sIL-2Rb treated
mice, as shown in figures 6A–6D [F (2, 17)=18.47, p=0.0004].
Table 1. Effect of various doses of sIL-1R1 on different open field behaviors.
Parameter Saline sIL-1R1 mg sIL-1R 2 mg sIL-1R 4 mg sIL-1R 8 mgf p
Locomotion (cm) 6624.0863198.82 7762.8363394.46 7518.1163540.1 7393.4761909.66 4499.762113.78 f (4, 34)=1.83 0.15
Rearing Episodes (#) 40.3621.9 44.43618.4 37.43612.4 37.7618.24 36.2626.62 f (4, 34)=0.19 0.94
Turning 29.5613.91 33611.87 35617.37 30.88610.04 21.66613.93 f (4, 34)= 0.91 0.47
Sniffing (sec) 461.56135.41 389.6677 415.75691.14 4556107.53 N/A f (3,12)=0.46 0.71
Head Bobbing 36.3363.78 37617.8 14.2619 32631.66 364.24 f(3,14)=1.12 0.37
Vertical Stereotypy Moves 36.25637.03 36624.74 15.563.31 42.67623.11 N/A f (3,12)=0.82 0.5
Vertical Stereotypy Episodes 16.25616.04 15.8610.23 761.63 18.6769.01 N/A f (3,12)=0.87 0.48
Table shows effects of various doses of single injection of sIL-1R1 on various behaviors in open field testing. Effects was considered significance ifp ,0.05.
doi:10.1371/journal.pone.0036316.t001
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e36316Figure 3. c-Fos expression and Fluorescent staining of Caudate Putamen in sIL-2Rs treated mice. Photomicrographs of brain sections
showing Fos-like immunoreactive cells in the caudate–putamen of mice receiving single injections of (A) saline, (B) sIL-2Ra (1 mg, s.c.), and (C) sIL-2Rb
(2 mg, s.c.). (D) Histogram showing the number (mean 6 S.E.M.) of Fos-positive cells in the caudate–putamen after administration of saline or single
injections of sIL-2Ra or sIL-2Rb. (E) Histogram showing the number (mean 6 S.E.M.) of Fos-positive cells counted within the indicated subterritories of
caudate–putamen after administration of saline or single injections of sIL-2Ra or sIL-2Rb (n=4). Insert reflects regions sampled for counting Fos-
positive cells in the dorsomedial (DM), dorsolateral (DL), central (CT), ventrolateral (VL) and ventromedial (VM) aspects of the caudate–putamen.
Photomicrographs showing deposits of sIL-2Ra or sIL-2Rb in caudate–putamen after administration of (F) saline or single injections of (G) sIL-2Ra and
(H) sIL-2Rb. Photomicrograph of omission control (I). Photomicrographs showing merged c-Fos and Fluorescent staining in sIL-2Ra treated mice (J)
and sIL-2Rb treated mice (K). [Arrow head: - Fluorescent staining; Arrow: - c-fos staining].
doi:10.1371/journal.pone.0036316.g003
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brain
The present findings show for the first time that a soluble
receptor modulates neural activity. How they affect brain activity
is not known. We thus sought to determine whether these
receptors are localized within the brain. As illustrated, recombi-
nant sIL-2Ra and sIL-2Rb deposits were found at the level of the
rostral caudate nucleus (figures 3F–3I), shell and core of nucleus
accumbens (figures 4E–4J), and motor cortex (figures 5H–5S). In
sIL-2Ra treated mice, the deposits of recombinant sIL-2Ra were
more prominent in the rostral caudate nucleus, M2 part of motor
cortex and core of nucleus accumbens; and for the recombinant
sIL-2Rb treated mice, the deposits of recombinant sIL-2Rb were
also more prominent in the rostral caudate nucleus, M2
component of motor cortex, and in the shell of the nucleus
accumbens. The deposits in prepyriform cortex were found only in
sIL-2Rb treated mice but not in sIL-2Ra treated mice (figures 6E–
6G). The label reflected injected and not endogenous sIL-2Rs
since mice received human sIL-2Rs.
We also sought to determine the extent to which there exists an
overlap of label of c-fos and sIL-2Ra in the forebrain regions in
question by overlying the photomicrographs for each label from
the same regions, one upon the other (in the absence of performing
double labeling procedures which were not conducted because of
incompatibilities between the staining procedures for these
methods). It was observed that there was significant overlap in
staining for c-Fos and sIL-2Rs in different regions of the caudate
nucleus. Specifically, as shown in Fig. 3 (J–K), extensive overlap
was observed between sIL-2Rs and c-fos. Similar findings were
also observed for the nucleus accumbens (Fig. 4, K–L). However,
as there was no fluorescent labeling in the prepyriform cortex for
sIL-2Ra treated mice, combining c-fos and fluorescent labeling
only indicated the presence of c-fos expression in this region as
compared to the overlapping of both types of label in sIL-2Rb
treated mice in this region (Fig. 6 H–I).
Discussion
The major discovery derived from the present study was that
our findings demonstrated that administration of soluble cytokine
receptors led to disturbances in motor behavior. This conclusion is
evident from two forms of observations described in the Results
Figure 4. c-Fos expression and Fluorescent staining of Nucleus Accumbens in sIL-2Rs treated mice. Photomicrographs of brain sections
showing Fos-like immunoreactive cells in the nucleus accumbens of mice receiving single injection of (A) saline, (B) 1 mg sIL-2Ra or (C) 2 mg sIL-2Rb.
Abbreviations: aca, anterior commissure; Sh, shell of nucleus accumbens; Co, core of nucleus accumbens. (D) Histogram show the number (mean 6
S.E.M.) indicate Fos-positive cells counted within the indicated compartments of the nucleus accumbens after administration of saline or single
injections of sIL-2Ra or sIL-2Rb. Photomicrographs of deposits of sIL-2Ra or sIL-2Rb in shell or core of nucleus accumbens after administration of (E
and F) saline or single injections of (G and H) sIL-2Ra or (I and J) sIL-2Rb. Photomicrographs showing merged c-Fos and Fluorescent staining in sIL-2Ra
treated mice (K) and sIL-2Rb treated mice (L). [Arrow head: - Fluorescent staining; Arrow: - c-fos staining].
doi:10.1371/journal.pone.0036316.g004
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e36316Figure 5. c-Fos expression and Fluorescent staining of Cortices in sIL-2Rs treated mice. Photomicrographs of brain sections showing Fos-
like immunoreactive cells in the motor cortex, cingulate cortex and infralimbic cortex of mice receiving single injection of (A) saline, (B) 1 mg sIL-2Ra
or (C) 2 mg sIL-2Rb. (D) Insert reflects regions sampled for counting Fos-positive cells in the motor cortex, cingulate cortex and infralimbic cortex.
Soluble Cytokine Receptors and Motor Behavior
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IL-2 receptor administration and (2) their presence in specific
regions of the brain related to motor functions. With respect to the
first set of observations, we discovered that single injections of sIL-
2Ra or sIL-2Rb (0–2 mg/Balb/c mouse; s.c.) induce marked
subunit-specific alterations in novelty-induced locomotion and
repetitive stereotypic behaviors. Specifically, sIL-2Ra increased
the incidence of in place stereotypic motor behaviors, including
rearing, turning, and grooming behavior. A wider spectrum of
behavioral changes was evident in mice treated with sIL-2Rb,
including increases in vertical and horizontal ambulatory activity
and stereotypic behaviors. In contrast with sIL-2Rs, soluble IL-1
Type 1 receptors (1–8 mg, sc) did not affect novelty-induced
behavioral motor responses, providing further support for the
Histogram shows the number (mean 6 S.E.M.) of Fos-positive cells counted within the indicated compartments of the (E) motor cortex, (F) cingulate
cortex and (G) infralimbic cortex after administration of saline or single injections of sIL-2Ra or sIL-2Rb. Photomicrographs of deposits of sIL-2Ra or
sIL-2Rb in (H, L and P) M1 division of motor cortex, (I, M and Q) M2 division of motor cortex, (J, N and R) cingulate cortex, and (K, O and S) infralimbic
cortex.
doi:10.1371/journal.pone.0036316.g005
Figure 6. c-Fos expression and Fluorescent staining of Prepyriform Cortex in sIL-2Rs treated mice. Photomicrographs of brain sections
showing Fos-like immunoreactive cells in the prepyriform cortex of mice receiving single injection of (A) saline, (B) 1 mg sIL-2Ra or (C) 2 mg sIL-2Rb. (D)
Number (mean 6 S.E.M.) of Fos-positive cells in the prepyriform cortex after administration of saline or single injections of sIL-2Ra or sIL-2Rb.
Photomicrographs of deposits of sIL-2Ra or sIL-2Rb in prepyriform cortex after administration of (E) saline or single injections of (F) sIL-2Ra or (G) sIL-
2Rb. Photomicrographs showing merged c-Fos and Fluorescent staining in sIL-2Ra treated mice (H) and sIL-2Rb treated mice (I). [Arrow head: -
Fluorescent staining; Arrow: - c-fos staining].
doi:10.1371/journal.pone.0036316.g006
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the second aspect of our findings, it was observed that there was a
general overlap of c-Fos expression and soluble IL-2 receptor
labeling within regions of the forebrain, which include the caudate
nucleus, motor cortex, nucleus accumbens, and prepyriform
region that have been traditionally associated with the behavioral
motor processes described in the present study. sIL-2Rs induced
pronounced subunit-specific alterations of Fos expression in the
striatum and cortex. We also discovered that sIL-2Ra and sIL-
2Rb localized in the cortex and striatum and that there was
specificity with regard to this localization. Indeed, there is a
striking similarity in the distributions of Fos-like immunoreactivity
and presence of sIL-2Rs, suggesting that they induce local effects
in these brain regions.
Based on c-Fos data, it can be presumed that the caudate,
nucleus accumbens and motor cortex are associated with
exploratory behavior and with in-place stereotypic activities in a
novel environment, whereas, the prepyriform cortex is associated
with enhanced locomotor activity. Additionally, higher c-fos
activation in the medial aspect of the caudate nucleus relative to
the lateral aspect in sIL-2Rb treated mice suggests involvement of
this region in locomotor and stereotypic behaviors. Moreover, c-
Fos activation was observed in the M2 region of motor cortex of
sIL-2Ra treated mice coupled with higher levels of activation in
the M1 region of motor cortex in sIL-2Rb treated mice, suggesting
a possible role of M2 in fine motor (in-place) activities and M1 in
gross motor (exploratory locomotor) activities.
From the present findings, it is now clear that in addition to
acting in antagonistic manners, soluble cytokine receptors,
including sIL-2Rs, may potentiate lymphoid and cytokine activity
in normal and disease states [3]. The IL-2 receptor is normally
expressed on several cell types, including T cells, B cells, natural
killer cells, and monocytes [4]. It is composed of a, b and c
subunits. The a subunit confers individuality to IL-2, while the b
and c subunits are shared with other cytokines (notably IL-15)
[22]. After being shed from activated T and B cells and released
into the circulation, sIL-2Rs bind IL-2. Increases in sIL-2R are
evident in various disorders involving T cell activation, including
autoimmune and neoplastic diseases. Thus, it has been suggested
that circulating levels of sIL-2R may be used as diagnostic
markers, and perhaps as predictors of disease activity. [7,23]
In recent years, it has become apparent that soluble cytokine
receptors have additional biological functions. For example, the
soluble TNFR1 helps modulate the transport of substances across
the blood brain barrier [24]. Such findings raise the possibility that
a soluble cytokine receptor may affect brain function, and thus,
play a role in the disease process. Circulating soluble cytokine
receptors, such as soluble interleukin-2 receptors (sIL-2R) are
normal constituents of body fluids that regulate peripheral
cytokine and lymphoid activity. Peripheral sIL-2Rs are elevated
in psychiatric and neurological disorders linked with autoimmune
processes [7–8], including ones involving an increased expression
of repetitive stereotypic behaviors [11]. However, there is no
evidence that sIL-2Rs (or any soluble receptor) modulate such
behavior or that they localize in the brain.
The question may be raised of whether or not there exists a
relationship between specific levels of endogenous IL-2 in regions
of the forebrain related to motor functions considered in this study
and levels of sIL-2R and metabolic levels of brain activity for these
regions as implied from c-fos analyses. The presence of such a
relationship would provide further significance to the potential
functional importance of sIL-2R in the regulation of motor
behaviors related to various disease states related to movement
disorders. Unfortunately, at the present time, such information
appears to be lacking in the literature. Therefore, one natural
extension of the present study would be an attempt to provide an
analysis of the relationship characterizing c-fos levels associated
with specific motor responses as well as an attempt to identify the
possible relationship between sIL-2R with endogenous levels of
IL2 for specific regions of the forebrain related to the motor
responses considered in this paper.
In summary, we show for the first time that: (1) soluble receptors
(sIL-2R) induce behavioral changes, which include stimulation of
locomotion and repetitive stereotypic behaviors; (2) these effects
are (a) subunit-specific and (b) cytokine receptor-specific. We also
discovered that soluble receptors induce subunit-specific variations
of cell activity in the striatum and cortex. A striking finding is that
sIL-2Rs localized in these regions suggesting that sIL-2Rs locally
modulate brain function. These findings imply that soluble
cytokine receptors are novel modulators of brain function and
act as immune-brain messengers, which may be helpful in the
future for identifying potential etiological agents and possible
therapeutic targets.
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